New data from Teva's IMPACT-TD Registry reveals a significant diagnostic gap in tardive dyskinesia (TD), with only 23% of young adults (ages 18-29) with mood disorders receiving formal TD diagnosis despite 85% experiencing moderate to severe impact. The study of 211 adults with TD and concomitant mood disorders found that younger patients experience high psychological burden and face an average 3.5-year delay in diagnosis, highlighting the need for improved clinical identification and treatment.

Teva Pharmaceutical announced a $700 million acquisition of Emalex Biosciences to expand its late-stage pipeline with ecopipam, beating Q1 earnings expectations with adjusted EPS of 53 cents versus 48 cents consensus. The company reaffirmed 2026 guidance, plans $700 million in cost savings by 2027, and authorized a share buyback program, signaling confidence in its growth strategy.

Teva Pharmaceutical Industries announced a definitive agreement to acquire Emalex Biosciences for $700 million upfront, with up to $200 million in additional milestone payments. The acquisition adds ecopipam, a first-in-class dopamine D1 receptor antagonist for pediatric Tourette syndrome, to Teva's neuroscience pipeline. The drug has shown positive Phase 3 data and FDA Orphan Drug designation, with NDA submission anticipated in H2 2026. The transaction is expected to close by Q3 2026.

The global dermatomycoses market is expected to experience significant growth through 2035, driven by rising superficial fungal infections, increased hygiene awareness, and a growing immunocompromised population. Market advancements include enhanced antifungal formulations, digital PCR diagnostics, and nanopharmaceuticals. Key challenges include antifungal resistance and systemic drug concerns, while opportunities lie in AI diagnostics and broad-spectrum antifungals. Major players include Kaken Pharma, Novartis, Glenmark, Sun Pharma, Teva, Bayer, and Galderma.

Biolojic Design announced preclinical data for BD200, a multibody-drug conjugate targeting Trop-2 and Nectin-4, showing superior uptake and cytotoxicity compared to approved single-target drugs. BD200 demonstrated strong anti-tumor activity across multiple cancer models and in resistance settings where other ADCs failed. The company expects to enter clinical trials in the second half of 2026.

Teva Pharmaceuticals announced the launch of Home Ground™ Schizophrenia Community, a free online platform designed to support people living with schizophrenia and their care partners. The platform provides peer-driven resources, symptom tracking tools, emotional wellness support, and community events to address social isolation, which affects over 75% of people with psychotic disorders. The initiative was developed in collaboration with patients, care partners, and mental health advocacy groups.

Teva Pharmaceuticals, Direct Relief, and the National Association of Free and Charitable Clinics announced a second round of $75,000 grants to each of 11 free and charitable clinics across Alabama, Mississippi, and Texas to expand mental health services. In 2025, these programs reached over 57,000 people with mental health services and conducted nearly 6,000 depression and anxiety screenings. The initiative, now in its fourth year with $4 million in total funding since 2022, has demonstrated significant impact in addressing mental health access barriers in underserved communities.

The Crohn's Disease therapeutics market across eight major markets is projected to grow from $9.5 billion to $13.8 billion by 2032 at a CAGR of 3.9%, driven by approvals of 8 pipeline, generic, and biosimilar therapies. Novel mechanisms of action and emerging treatments will reshape the competitive landscape, with key opportunities in strategic licensing and partnerships.

Viatris trades at a significant discount despite generating a 13.5% free cash flow yield and $2.2 billion in annual FCF. With a $650 million cost savings program launching in 2026, six regulatory decisions expected, and two Phase 3 assets with blockbuster potential, the stock trades 17% below peer-average EV/EBITDA. The company's differentiated specialty pipeline leverages its unmatched global distribution infrastructure across 40 countries and 165 markets, positioning it for genuine inflection in 2026 with projected first year of top-line growth since formation.

Teva Pharmaceutical announced FDA approval of PONLIMSI (denosumab-adet), a biosimilar to Prolia for treating osteoporosis and related bone conditions across all indications. Additionally, the company's proposed biosimilar candidate to Xolair (omalizumab) for allergic asthma and other conditions received filing acceptance from both the U.S. FDA and European EMA. These milestones advance Teva's Pivot to Growth strategy and expand its biosimilars portfolio.

Teva Pharmaceutical announced FDA approval of PONLIMSI (denosumab-adet) biosimilar for treating various bone diseases, and acceptance of regulatory filings for an omalizumab biosimilar candidate by both FDA and EMA. These milestones represent significant progress in Teva's 'Pivot to Growth' strategy to establish itself as a leading biopharmaceutical company with a competitive biosimilar portfolio.

Teva Pharmaceutical announced FDA approval of PONLIMSI (denosumab-adet), a biosimilar to Prolia for treating various bone diseases, and acceptance of regulatory filings for its omalizumab biosimilar candidate to Xolair by both FDA and EMA. These approvals represent significant progress in Teva's 'Pivot to Growth' strategy to expand its biosimilar portfolio.